Human Immunodeficiency Virus (HIV) - Laboratory Testing and Reimbursement
This policy governs reimbursement criteria for HIV-related laboratory tests (screening, RNA quantification, genotyping/phenotyping) for Blue Cross Blue Shield of Oklahoma members; providers should confirm plan-specific coverage.
Document updated with literature review; reimbursement information unchanged; references revised.
Reimbursement information revised for clarity and items regarding genotyping and phenotyping were added in a prior update.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.